Home › Cancro delle vie biliari › Texas
Studi clinici su Cancro delle vie biliari nello stato di Texas
23 studi su Cancro delle vie biliari cercano partecipanti presso sedi nello stato di Texas.
Città nello stato di Texas
Testo ufficiale dello studio (inglese)
A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
- The University of Texas MD Anderson Cancer Center - Texas Medical Center, Houston
In reclutamentoFase 2
Età 18 e oltre · Tutti i sessi · Aggiornato il 2 ott 2026 · NCT06760819AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2
- Research Site, Houston
In reclutamentoFase 2
Età 18 e oltre · Tutti i sessi · Aggiornato il 30 set 2026 · NCT06219941A Study to Select a Dose Regimen (Part A) and to Investigate Overall Survival (Part B) With Nanvuranlat Compared With Physician's Best Choice in Participants Aged 18 Years or Older With Biliary Tract Cancer
- University of Texas Southwestern Medical Center (Site 104), Dallas
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 29 set 2026 · NCT07265674Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or Targeted Therapy and/or ICI, for the Treatment of Patients With Advanced Gastrointestinal Cancers, Including Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study)
- MD Anderson Cancer Center, GI Medical Oncology Dept, Houston
In reclutamentoFase 1/2
Età 18 e oltre · Tutti i sessi · Aggiornato il 28 set 2026 · NCT05482893A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02)
- Research Site, Houston
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 28 set 2026 · NCT07221253A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A)
- University of Texas MD Anderson Cancer Center ( Site 0316), Houston
In reclutamentoFase 1/2
Età 18 e oltre · Tutti i sessi · Aggiornato il 25 set 2026 · NCT06428409Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
- Research Site, Houston
In reclutamentoFase 2
Età da 18 a 130 · Tutti i sessi · Aggiornato il 23 set 2026 · NCT05489211Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
- Start - Dfw, Fort Worth
- Oncology Consultants, Houston
- START - San Antonio, San Antonio
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 10 set 2026 · NCT06293898CTX-009 With Gemcitabine, Cisplatin, and Durvalumab as First-line Therapy in Patients With Unresectable or Metastatic Biliary Tract Cancers
- MD Anderson Cancer Center, Houston
In reclutamentoFase 1/2
Età 18 e oltre · Tutti i sessi · Aggiornato il 9 set 2026 · NCT06548412AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001)
- Avenzo Therapeutics Recruiting Site, Dallas
- Avenzo Therapeutics Recruiting Site, Houston
- Avenzo Therapeutics Recruiting Site, San Antonio
In reclutamentoFase 1/2
Età da 18 a 75 · Tutti i sessi · Aggiornato il 4 set 2026 · NCT07038343Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400
- START-San Antonio, San Antonio
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 24 ago 2026 · NCT06084481A Phase 1 Study of LNCB74 in Advanced Solid Tumors
- MD Anderson, Houston
- UT Health San Antonio - MD Anderson Cancer Center, San Antonio
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 21 ago 2026 · NCT06774963Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer
- Research Site, Dallas
- Research Site, Fort Worth
- Research Site, Houston
In reclutamentoFase 3
Età da 18 a 99 · Tutti i sessi · Aggiornato il 19 ago 2026 · NCT06467357A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
- The University of Texas, MD Anderson Cancer Center, Houston
- UT Health Mays Cancer Center, San Antonio
In reclutamentoFase 1/2
Età 18 e oltre · Tutti i sessi · Aggiornato il 11 ago 2026 · NCT05592626A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
- Texas Oncology - West Texas, Amarillo
- Texas Oncology, P.A., Dallas
- Texas Oncology Gulf Coast, Pearland
In reclutamentoFase 1/2
Età 18 e oltre · Tutti i sessi · Aggiornato il 5 ago 2026 · NCT06330064A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
- Baylor Scott & White Research Institute, Dallas
- University of Texas MD Anderson Cancer Center, Houston
- Baylor Scott & White Medical Center, Temple
In reclutamentoFase 2
Età 8 e oltre · Tutti i sessi · Aggiornato il 27 lug 2026 · NCT05503797A Phase 1 Dose-escalation Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation
- The University of Texas MD Anderson Cancer Center, Houston
- NEXT Oncology, San Antonio
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 29 giu 2026 · NCT07458347A Phase 1/1B Study of ST-01156, a Small Molecule RBM39 Degrader, in Patients With Advanced Solid Malignancies
- The University of Texas MD Anderson Cancer Center, Houston
In reclutamentoFase 1
Età 16 e oltre · Tutti i sessi · Aggiornato il 2 giu 2026 · NCT07197554Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
- MD Anderson Cancer Center, Houston
- NEXT Oncology, San Antonio
In reclutamentoFase 1/2
Età 18 e oltre · Tutti i sessi · Aggiornato il 6 mag 2026 · NCT06239194Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC
- Houston Methodist Hospital Cancer Center, Houston
In reclutamentoFase 2
Età 18 e oltre · Tutti i sessi · Aggiornato il 2 apr 2026 · NCT05733598This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Toripalimab in Patients With Advanced Solid Tumors
- NEXT Oncology, Austin, TX 78758
- NEXT Oncology, San Antonio
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 2 apr 2026 · NCT06451497Ligufalimab and Cadonilimab in Advanced Liver Cancers
- University of Texas Southwestern Medical Center, Dallas
In reclutamentoFase 2
Età 18 e oltre · Tutti i sessi · Aggiornato il 27 feb 2026 · NCT06789848A Study of MT-4561 in Patients With Various Advanced Solid Tumors
- The University of Texas MD Anderson Cancer Center, Houston
In reclutamentoFase 1/2
Età 18 e oltre · Tutti i sessi · Aggiornato il 11 dic 2025 · NCT06943521Fonte: ClinicalTrials.gov, dati recuperati il 5 ott 2026. Ogni studio stabilisce i propri criteri di idoneità; è il team di ricerca a decidere chi può partecipare.